Worth reading
61In focus
Scored from 4 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
13543
Millions of yen (year-on-year increase in revenue)Wording
Definitive
How definitive the wording is.Contents of this document
Supplementary Materials to the Earnings ReportFiscal year ending March 2027, second quarter (first half)5 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥103,441 million+15.1%
Operating profit¥18,848 million+10.1%
Ordinary income¥20,316 million+23.7%
Net income¥16,203 million+29.9%
Selling, general and administrative expenses¥29,766 million
Gross Profit Margin
Rate47
Year-on-year change (points)-1.4
Operating profit margin
Rate18.2
Year-on-year change (points)-0.8
Results for the three months of the current quarter
Net Sales
¥53,736 million
Operating profit
¥10,967 million
Ordinary income
¥10,563 million
Net income
¥9,746 million
Full-year earnings forecast
Net Sales
¥218,500 million
Operating profit
¥38,400 million
Ordinary income
¥36,400 million
Net income
¥29,300 million
Investments and other expenditures
¥50,200 million
Investment in property, plant and equipment
¥46,900 million
Depreciation and amortization
¥13,500 million
What the company explained in this material
New initiatives
Consolidation of YOMEISHU SEIZO CO.,LTD. (from September 2026)Key KPIsA metric the company considers important as a management benchmark.
- Growth rate of 129 prescription medical Kampo formulations (value basis)4.7 %
- Growth rate of 129 prescription medical Kampo formulations (volume basis)4.9 %
- Number of formulations with value growth87 formulations
Segment results
- Domestic BusinessSales¥83,945 million (YoY +5.5%)Operating profit¥17,377 million (YoY +1.4%)
- China businessSales¥19,495 million (YoY +88.2%)Operating profit¥1,471 million
Number of employees
Number of Employees5,197 people
Capital expenditures
¥46,900 million capital investment in tangible fixed assets, full-year forecast
| Item | Details |
|---|---|
| Document type | Supplementary Materials to the Earnings Report |
| Fiscal Period Covered | Fiscal year ending March 2027, second quarter (first half) |
| Net Sales | ¥103,441 million (YoY +15.1%) |
| Operating profit | ¥18,848 million (YoY +10.1%) |
| Ordinary income | ¥20,316 million (YoY +23.7%) |
| Net income | ¥16,203 million (YoY +29.9%) |
| Gross Profit Margin | Rate 47 / Year-on-year change (points) -1.4 |
| Operating profit margin | Rate 18.2 / Year-on-year change (points) -0.8 |
| Selling, general and administrative expenses | ¥29,766 million |
| Results for the three months of the current quarter | Net Sales ¥53,736 million / Operating profit ¥10,967 million / Ordinary income ¥10,563 million / Net income ¥9,746 million |
| Full-year earnings forecast | Net Sales ¥218,500 million / Operating profit ¥38,400 million / Ordinary income ¥36,400 million / Net income ¥29,300 million / Investments and other expenditures ¥50,200 million / Investment in property, plant and equipment ¥46,900 million / Depreciation and amortization ¥13,500 million |
| Segment results | Segment Domestic Business / Sales ¥83,945 million (YoY +5.5%) / Operating profit ¥17,377 million (YoY +1.4%), Segment China business / Sales ¥19,495 million (YoY +88.2%) / Operating profit ¥1,471 million |
| Key KPIs | Indicator name Growth rate of 129 prescription medical Kampo formulations (value basis) / Value 4.7 % / Year on year against the same period last year Not disclosed, Indicator name Growth rate of 129 prescription medical Kampo formulations (volume basis) / Value 4.9 % / Year on year against the same period last year Not disclosed, Indicator name Number of formulations with value growth / Value 87 formulations / Year on year against the same period last year Not disclosed |
| Number of employees | Number of Employees 5,197 people / Change during the period Not disclosed / Hiring plan Not disclosed |
| Capital expenditures | ¥46,900 million (capital investment in tangible fixed assets, full-year forecast) |
| New initiatives | Consolidation of YOMEISHU SEIZO CO.,LTD. (from September 2026) |
Items this document does not state (15)
Progress against full-year forecastSelf-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.YOMEISHU SEIZO CO.,LTD. has been consolidated since September 2026, and its impact is included in the consolidated figures and consolidated employee count. Revenue from YOMEISHU SEIZO CO.,LTD. is included under Healthcare Products (OTC Kampo formulations, etc.).
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.